Save

A First-in-Human Safety Trial of MTX-474

PHASE1RECRUITING

A randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults.

Simpliy with AI

Study details:

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to assess the safety, tolerability, and PK of single and multiple ascending doses of MTX-474 administered in healthy adults. SAD Portion. The SAD portion of the study will consist of 6 planned dosing cohorts each comprising 8 healthy participants.

The starting dose will be 0. 125 mg/kg (Cohort 1) with subsequent planned doses of 0. 25 mg/kg (Cohort 2), 0.

5 mg/kg (Cohort 3), 1 mg/kg (Cohort 4), 2 mg/kg (Cohort 5), and 4 mg/kg (Cohort 6). Planned doses may be adjusted in response to the data. Additional participants and/or additional dosing cohorts may be added as needed based on the data.

Within each cohort, participants will be randomly assigned to receive MTX-474 or matched placebo. The first 2 participants (sentinel participants) within each cohort will be randomized 1:1 to receive MTX-474 or placebo on Day 1. These participants will be monitored for 24 hours, and after review of the safety data from both participants and approval by the study Investigator, the additional 6 participants will be randomized to study drug (n=5 MTX-474; n=1 placebo).

Each participant will undergo assessments at specified timepoints on Days 1 through 29. End-of-Study (EOS) procedures will be completed on Day 29 or upon early termination (ET). An End-of-Follow-up (EOF) assessment of PK and ADA will be completed on Day 29.

MAD Portion. The MAD portion of the study will consist of 4 planned dosing cohorts. Each cohort will comprise 8 healthy participants (n=6 MTX-474; n=2 placebo).

The starting dose will be 0. 5 mg/kg (Cohort 1) with subsequent planned doses of 1 mg/kg (Cohort 2), 2 mg/kg (Cohort 3), and 4 mg/kg (Cohort 4). Planned doses may be adjusted in response to the data.

Additional participants and/or additional dosing cohorts may be added as needed based on the data. On Day 1, participants will be randomized to receive either MTX-474 or matched placebo. The randomized participants will receive a dose of study drug on Days 1, 8, 15, and 22.

Participants will be housed inpatient from Day -1 through Day 2, Days 7 through 9, 14 through 16, and 21 through 23. All other visits will be conducted in the outpatient setting. Each participant will undergo assessments at specified timepoints on Days 1 through 50.

End-of-study procedures will be completed on Day 50, or upon ET. An EOF assessment of PK and ADA will be completed on Day 50. Safety and tolerability of MTX-474 will be reviewed through Day 29 by the study Investigator and SRMO to inform dose escalation decisions for the next dose cohort.

Additional cohorts for the SAD and MAD portions of the study may be added as needed to potentially explore alternative doses.

Simplify with AI

Eligibility criteria

Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.

Inclusion criteria

All genders, ages 18 to 60 years, inclusive

Willing and able to complete all protocol-required study visits and procedures

Consumption of not more than 5 cigarettes or other cotinine-containing products (including tobacco, nicotine gum, patches, and e-cigarettes) per week as long as they are willing to abstain nicotine use approximately 5 days prior to admission and during inpatient stays

Willing to refrain from marijuana- or cannabinol-containing products for 30 days before Screening and until the last study visit

Agree to a highly effective method of contraception for 28 days prior to the first dose of study drug, and persist through 65 days after the last dose of study drug.

Exclusion criteria

Any concurrent active medical condition determined clinically significant by the Investigator

Body mass index (BMI) >32 kg/m2 or body weight >100kg

Use of any systemic immunosuppressant medications, medications to treat diabetes, antipsychotics, anticoagulants, or other medications within 90 days of Screening

Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening other than adequately treated non-melanomatous skin cancers or cervical carcinoma in situ

Current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) as evidenced by a positive hepatitis B surface antigen or a positive HIV test at Screening

Currently pregnant, lactating, or planning to conceive or contribute to pregnancy during the trial and up to 65 days (for women of childbearing potential) or 125 days (for males) after the participant's last dose of study drug, if applicable

History of severe depression, psychosis, or suicidal ideation within 5 years of Screening

History of anaphylaxis or other significant allergies in the opinion of the Investigator

History of substance use disorder as specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, within 1 year of Screening

Positive screen for drugs of abuse or alcohol intake at Screening or admission to the CRU (Day -1)

Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant's ability to complete the study, on-study evaluations, or participant safety

Any surgical procedure, including planned procedures within 12 weeks of Screening

Participation in another research study of an investigational agent within 30 days of Screening or 5 half-lives of the agent, whichever is longer.

Simplify with AI

Eligibility

Age eligible for study : 18 and older

Healthy volunteers accepted : Yes

Gender eligible for study: All

Things to know

Study dates

Study start: 2024-07-10

Primary completion: 2025-05-28

Study completion finish: 2025-05-28

Study type

OTHER

Phase

PHASE1

Trial ID

NCT06535841

Intervention or treatment

BIOLOGICAL: MTX-474

OTHER: Placebo

Conditions

• Healthy

Condition: Healthy
BIOLOGICAL: MTX-474 and other drugs
Herston, Queensland, Australia
Sponsor: Mediar Therapeutics

You may be eligible to participate in this trial based on your search. Check eligibility by answering some questions.

Are you running this trial? If you're a clinic or sponsor, you can claim this study. Claim or learn more.

Find a site

Closest Location:

Nucleus Network

Research sites nearby

Select from list below to view details:

Nucleus Network
Herston, Queensland, Australia

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Participant Group/Arm	Intervention/Treatment
EXPERIMENTAL: MTX-474 Biological: MTX-474	BIOLOGICAL: MTX-474 MTX-474 is an immunoglobin G1 (IgG1) monoclonal antibody directed against Ephrin B2 that binds to and has demonstrated ability to block phosphorylation of its preferred receptor EphB4. Increased levels of circulating soluble EphrinB2 have been found in patients with systemic sclerosis.
PLACEBO_COMPARATOR: Placebo Placebo	OTHER: Placebo Matching Placebo - Normal Saline

What is the study measuring?

Primary outcome

Primary Outcome Measure	Primary Outcome Description	Primary Outcome Time Frame
Incidence of Treatment-Related Adverse Events in healthy volunteers	Clinical Safety Labs are collected, and Adverse Events are assessed in both inpatient and outpatient clinic visits	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
MTX-474 PK by dose will be evaluated for Cmax, as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
Serum sample results will be summarized for presence of Anti-Drug Antibodies during the SAD and MAD portions of the study	Blood serum samples will be collected at protocol-specified timepoints throughout the study to assess for the presence and titer (if applicable) of Anti-Drug Antibodies.	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
MTX-474 PK by dose will be evaluated for AUC0-t, as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
MTX-474 PK by dose will be evaluated for AUC0-tau (MAD only), as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)
MTX-474 PK by dose will be evaluated for AUC0-∞, as feasible	Blood serum samples will be collected at protocol-specified timepoints throughout the study	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

Secondary outcome

Secondary Outcome Measure	Secondary Outcome Description	Secondary Outcome Time Frame
Blood serum samples will be collected to assess the target engagement of MTX-474 in healthy adult participants	These assessments will be summarized as: Change from Baseline in bound EphrinB2 levels Change from Baseline in free EphrinB2 levels Change from Baseline in the percent phorphoEphB4 (pEpB4) positive cells and ratio of pEpB4 to total EphB4 positive cells	Through Day 29 (SAD Cohort) or Day 50 (MAD Cohort)

Frequently Asked Questions

Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol

No questions submitted. Be the first to ask a question!

You may be eligible to participate in this trial based on your search.Apply for study

Are you running this trial? If you're a clinic or sponsor, you can claim this study.Claim this trial

References

Clinical Trials Gov: A First-in-Human Safety Trial of MTX-474